Examining the use of oral contraceptives in the management of acne

Heather L Salvaggio1
Andrea L Zaenglein1,2

1Departments of Dermatology and Pediatrics, Penn State/Milton S. Hershey Medical Center, Hershey, PA, USA

Abstract: Combined oral contraceptive pills (cOCPs) are often used in the treatment of acne in females. They are effective, safe, and easy to use in appropriate patients in combination with more conventional acne therapies. This article will briefly address the physiologic rationale for the use of cOCPs in the treatment of acne. It will also review efficacy by examining relevant clinical trials. Safety considerations and the adverse event profile for oral contraceptives will be presented. Finally, practical considerations for prescribing cOCPs will be discussed.

Keywords: oral contraceptives, acne, treatment

Introduction
Acne is a problem for women in all age groups. It generally begins at adrenarche, between the ages of 8 and 10 years, and peaks around age 17. Studies have shown that 100% of females are affected sometime during their adolescent years.1 While often considered a side effect of puberty, adult acne is also fairly common, occurring in 5% to 12% of adult women. Surprisingly, it can continue to be a problem for some women even into their postmenopausal years.

The psychosocial impact of acne is undeniable; adversely impacting the quality of life of those affected. Studies have shown that the level of impairment is similar to that seen in arthritis, back pain, diabetes, asthma, and epilepsy.2 Adults with severe acne have decreased employment rates compared to their unaffected peers.3 In addition to the psychological toll, acne can lead to permanent scarring and result in significant, life-long disfigurement.

Therefore, effective use of all available acne treatments is paramount to gaining control of this disorder and helping those affected. While excellent treatments are available, acne in females can pose a unique challenge for the treating physician. It is often recalcitrant to conventional acne therapies, including systemic antibiotics and even isotretinoin. Combined oral contraceptives and other hormonally targeted treatments can be effective in this group of patients and should be considered in the treatment plan for females with acne. Their use will be reviewed in this article.

Physiology/basic science rationale
Acne physiology
Four major processes are felt to play a role in the pathogenesis of acne: 1) Follicular hyperkeratinization contributes to the formation of a primary acne lesion, the comedone. This hyperkeratinization causes follicular plugging which then entraps the follicles...
contents, including sebum and bacteria. 2) Increased sebum production results in extension of the follicular unit and assists with plug formation. 3) Comedone rupture initiates an inflammatory cascade in the surrounding tissues resulting in the recruitment of immune cells and the formation of inflammatory papules, pustules and nodules. 4) Propionibacterium acnes, bacteria present on the skin surface and within follicular units, thrive in this environment, and contributes to the inflammatory cascade through its activation of toll-like receptor 2 (TLR2) and other mediators.

Different acne treatments target these different, yet entwined processes. For instance, benzoyl peroxide is bactericidal against P. acnes. Salicylic acid and topical retinoids are comedolytic and decrease follicular hyperkeratinization. Topical retinoids also decrease TLR-2 expression. Antibiotics play both an anti-inflammatory role and are bacteriostatic against P. acnes. Hormonal therapies, like combined oral contraceptive pills (cOCPs), target sebum production and may also play a role in decreasing follicular hyperkeratinization. Oral isotretinoin is the only medication that exerts action against all four of the steps, but its mechanism of action has not been fully elucidated.

Sebum production is upregulated during physiologic and pathologic states of increased androgen production and acne is seen in these conditions. In women, androgens are produced primarily by the ovaries and adrenal glands. Acne typically begins during adrenarche, when the adrenal gland begins to produce large quantities of dehydroepiandrosterone (DHEAS). Acne also develops in conditions of androgen excess; including polycystic ovarian syndrome, adrenal and ovarian tumors, and congenital adrenal hyperplasia. Administration of testosterone, dehydroepiandrosterone, and androstenedione have been shown to increase sebum production and the size of sebaceous glands. Acne flares are also seen during periods of stress, which is also a state of increased adrenal androgens. Interestingly, castrated male patients, those without testicular androgens, and those with androgen receptor defects are not afflicted with acne.

Most females with acne will have circulating androgen levels within the normal range. However, studies have shown that as a group, females with acne trend towards the higher end of normal. It may also be that androgen metabolism is increased at the level of the pilosebaceous unit as well, either independently or dependently on the level of circulating androgens. Androgen receptors have been localized to the outer root sheath of keratinocytes and to the basal layer of the sebaceous gland. Androgens are thought to stimulate growth and differentiation of sebaceous glands. The exact molecular mechanisms are yet to be elucidated.

How do oral contraceptives work?

COCs include an estrogen component, usually ethinyl estradiol, and a progestin component which will vary. Estrogens are known to decrease sebum production. They are hypothesized to accomplish this in several ways, both locally at the level of the sebaceous gland, and systemically. First, they may directly oppose androgens at the local level and regulate genes involved in sebum production and sebaceous gland growth. Second, they provide negative feedback on the pituitary/hypothalamus. That is, they inhibit the anterior pituitary’s production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thus decreasing ovarian production of the androgen, testosterone. Third, estrogen administration increases sex hormone binding globulin, which binds serum testosterone, decreasing the amount of free testosterone available to bind with the androgen receptor. The efficacy of COCPs in the treatment of acne is felt to be secondary to these estrogenic effects. Ethinyl estradiol is the estrogen in most oral contraceptives and comes in various dosages and dosing regimens. First-generation oral contraceptives had higher doses of ethinyl estradiol, around 0.1 mg. Newer formulations contain much lower doses of estrogen, typically 0.020 to 0.035 mg, which minimize the adverse effects that can be associated with estrogen use. These lower dose estrogens still maintain the ability to suppress sebum production.

Use of estrogen has several safety issues, including: increased cardiovascular disease and hypercoagulability, and an increased risk of endometrial and breast cancers. To minimize the risk, most COCPs include a combination of an estrogen with a progestin. Synthetic progestins act at the progesterone receptor but also react with the androgen receptor to varying degrees and thus may potentiate acne. They can also cause glucose intolerance and interfere with the effect of estrogen on sex-hormone binding globulin. Older synthetic progestins like the first-generation gonane, norethindrone, and the second-generation estranges, norgestrel and levonorgestrel, were derived from progesterone. In vitro studies suggest that these progestins may cross-react with the androgen receptor. Newer synthetic progestins, like the third-generation gonanes, desogestrel and norgestimate, have less activity at the androgen receptor and more specificity for the progestin receptor, thus the androgenic effects are minimized. Drosperrone is a relatively new fourth-generation progestin with a pharmacologic profile that is more similar to drosperrone. It blocks
endogenous androgens from binding the androgen receptor and is thus anti-androgenic. Drospirenone is an analogue of spironolactone, a diuretic with anti-mineralocorticoid activity and anti-androgen activity also used in the treatment of acne. Drospirenone’s anti-mineralocorticoid properties may help to counteract the bloating and water retention produced by estrogen in the cOCPs. Multiphasic cOCPs with varying progestin levels were designed to minimize androgenic effects by decreasing the overall amount of progestin delivered over the course of the cycle. They start with lower progestin levels and increase to provide the higher androgen dose at the end of the menstrual cycle, which more closely mimics physiology. Fortunately, in all cOCPs, the effects of the estrogen outweigh the effects of the progestin and therefore the overall effect is a decrease in androgen levels and improvement in acne.

**Efficacy**

Clinical trials have shown that cOCPs are effective in the treatment of acne. Changes in lesion counts, physician global assessments, and patient satisfaction have generally been the outcome measures of these studies. Though many cOCPs have shown efficacy in the treatment of acne in clinical trials, and all are hypothesized to work through their estrogenic effects, only 3 oral contraceptives have been approved by the FDA in the United States for use in patients with acne who desire contraception. These include: norgestimate 0.180 mg/0.215 mg/0.25 mg ethinyl estradiol 0.035 mg (Ortho-TriCyclen®; Ortho-McNeil-Janssen Pharmaceuticals, Inc.), norethindrone 1 mg ethinyl estradiol 0.020 mg/0.030 mg/0.035 mg (Estrostep®, Warner Chilcott), and drospirenone 3 mg ethinyl estradiol 0.02 mg (YAZ®, Bayer HealthCare). Cyproterone acetate (Diane®, Dianeette®) is a synthetic derivative of 17-hydroxyprogesterone, approved in Europe for the treatment of acne, hirsutism and alopecia, but is not available in the United States. It may be used as a sole agent or in combination with ethinyl estradiol. While few are approved for the use in acne, clinical trials suggest that many other oral contraceptives are also effective. Those with ethinyl estradiol and levonorgestrel, desogestrel, norgestimate, gestodene, norethindrone acetate, chlormadinone acetate, drospirenone, cyproterone acetate, all have demonstrated efficacy in the treatment of acne.

A recent Cochrane review provided a comprehensive assessment of the efficacy of cOCPs for the treatment of acne in women. This review looked at all randomized controlled clinical trials which compared any combined cOCP to either a second cOCP, oral antibiotic, topical acne treatment, no treatment or placebo. Included studies were required to assess at least one of the following measurements: change in specific lesion types, change in total lesion counts, physician or patient global assessment, psychosocial function outcome, and early discontinuation secondary to adverse events, including worsening of acne. A total of 81 trials were identified with 23 trials (a total of 7162 patients) meeting inclusion criteria. Metanalysis revealed the following conclusions: cOCPs reduced inflammatory and non-inflammatory lesion counts, resulted in decreased acne severity grades, and improved patients’ self-assessment of acne in all of the trials comparing oral contraceptives to placebo. In most of the studies analyzed, total acne lesion counts decreased 40% to 60% with cOCP use, while an approximate 30% reduction in total lesion counts was seen in placebo groups. Typically, inflammatory lesion counts show greater improvement than noninflammatory lesion counts. Studies comparing oral contraceptives did not convincingly show superiority of one oral contraceptive to another in the treatment of acne. cOCPs containing chlormadinone acetate or cyproterone acetate seemed to improve acne better than those containing levonorgestrel; however, this was based on limited clinical data. Discontinuation secondary to adverse events also did not vary between cOCPs. There were not enough trials to reach a conclusion about cOCPs versus oral antibiotics.

There are several important safety concerns and interactions to consider when starting a patient on oral contraceptives. More serious adverse events may occur in certain patients and should thus be avoided in those at risk (Table 1). All patients starting on cOCPs for acne should be thoroughly vetted regarding risk factors, with particular focus on lifestyle choices and family history. Patients should be routinely counseled about possible side effects from cOCP use and asked about the development of any side effects at their follow-up appointments.

Hormonal changes lead to the most common side effects. Nausea, breast tenderness, headache, and bloating are attributed to the estrogen component of the cOCP. Fatigue, irritability, weight gain, acne, oily skin, increased low-density lipoprotein level (LDL) and breast tenderness are attributed
to the progestogen component of the COCP. Decreased libido is also attributed to low progesterone levels.

Menstrual irregularity can also occur. As the levels of estrogen in COCPs has decreased, the incidence of unscheduled bleeding and spotting has increased. If estrogen levels are too low, hypomenorrhea and early cycle breakthrough bleeding can occur. If progesterone levels are low, late cycle breakthrough bleeding results. Knowledge of these effects can help the clinician choose the right COCP for their patient and troubleshoot any problems with ongoing COCP therapy.

COCPs now carry a black box warning regarding their risk of cardiovascular events, including venous thromboembolism (VTE). The greatest risk for VTE occurs within the first year of use and among carriers of thrombogenic mutations. The WHO Medical Eligibility Criteria for Contraceptive Use advises that the risks of COCP use may outweigh the benefits in women with known thrombophilias. Examples of such thrombophilias include: factor V Leiden deficiency, protein C and protein S deficiencies, antithrombin III deficiency, dysfibrinogenemia, prothrombin 20210, hyperhomocysteinemia, resistance to activated protein C, and high levels of factor VII and von Willebrand factor. Women with factor V Leiden deficiency who use COCPs have a 35-fold increase risk of developing VTE over their baseline risk. Depending on whether they are heterozygous or homozygous, the increase in risk ranges from 4- to 10-fold, to 50- to 100-fold, respectively. Other factors that increase risk for VTE in women taking COCPs include: age greater than 45, smoking greater than 10 cigarettes per day, and personal history of VTE. A personal and family history query to evaluate risk factors for VTE and cardiovascular disease and baseline blood pressure and body mass index should be performed prior to starting COCPs. Although a serious potential side effect, the incidence of VTE is rare, and routine screening of asymptomatic women without a family history of thrombophilia is not recommended.

Both the amount of estrogen and type of progestin play a role in VTE. There is reduced risk with lower amounts of ethinyl estradiol. Recently, there has been concern that certain progestins may increase this risk. Drospirenone and cyproterone, which both have antiandrogen activity, have been suggested to carry a greater risk of VTE. While there have been no randomized controlled trials, case control studies and a cohort analysis suggest that cyproterone may carry up to a four-fold increased risk. However, the European Active Surveillance, a large prospective, controlled, multinational cohort study of new users of drospirenone, and other progestin containing oral contraceptives, reported similar rates and identical hazard ratios for venous thromboembolism in users of drospirenone containing COCPs versus others.

Users of COCPs do carry a risk of developing hypertension; therefore blood pressure should also be monitored during follow-up visits. Other cardiovascular events that have evidence for association/risk include: arterial thromboembolism, cerebral hemorrhage and thrombosis, mesenteric thrombosis, and myocardial infarction. There is also evidence for association/risk for the development of gallbladder disease, hepatic adenomas and other benign liver tumors, and retinal thrombosis in patients taking COCPs. There are many other reactions that patients may experience that are considered related to the use of COCPs. Leg edema and varicose vein aggravation are additional cardiovascular risks. Neurologic side effects include: depression, migraine, mood changes, and worsening chorea. Dermatologic effects include chloasma, melasma, and other rare dermatoses. Nausea, vomiting, abdominal pain and cramping, appetite changes, bloating, cholestatic jaundice, and focal nodular hyperplasia are additional gastrointestinal and hepatic adverse events. Genitourinary side effects include: cervical ectropion, cervical secretions, endocervical hyperplasia, fibroid enlargement, vaginal candidiasis and vaginitis. COCP use may cause exacerbation of porphyria, and decrease folate levels. Rhinitis might also occur with their use. Ophthalmologic side effects include contact lens intolerance, and change in corneal curvature. Anaphylactic and anaphylactoid reactions may also occur.
Use of COCPs containing the progestin, drospirenone, may also result in an increase in serum potassium levels. Monitoring of potassium levels should be done in patients with underlying kidney disease, or those taking medications that can increase serum potassium levels, such as nonsteroidal anti-inflammatory agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, and heparin. Also, acne patients treated with spironolactone in combination with a drospirenone containing COCP should be closely monitored for excessive potassium levels.

Oral contraceptives and oral tetracyclines are commonly used together in the treatment of acne. Backup contraception for patients using these medications concomitantly is routinely recommended by pharmacists. The mechanism of interference may be due to an alteration of the bacterial flora resulting in the impaired absorption of estrogens. However, in patients taking doxycycline and tetracycline, studies have shown that estrogen levels are unaffected.\textsuperscript{32,33} While there have been case reports of pregnancy occurring on such combinations, pregnancy rates were no greater than those from failure rates reported from the COCP alone.\textsuperscript{34,35} Individual variations in estrogen metabolism likely explain oral contraceptive failure.\textsuperscript{36} However, what additional impact the use of oral antibiotics has on those individuals needs to be further studied. Currently, there are no pharmacokinetic data or randomized controlled clinical trials supporting that oral antibiotics decrease the efficacy of oral contraceptives, with the notable exception of anti-tuberculosis drugs like rifampin.\textsuperscript{32}

If the onset of acne in females is acute and severe, or if the acne is accompanied by signs of hyperandrogenism, investigations should be performed to rule out an underlying endocrine abnormality. A complete medical history and physical examination should be performed in these patients looking for signs of hyperandrogenism. These signs include: irregular menstrual periods, obesity, hypertrichosis, female pattern alopecia, clitoromegaly, and deepening of the voice. An appropriate minimum laboratory workup includes drawing serum total testosterone, free testosterone, and DHEAS. Some also advocate drawing LH and FSH. These should be performed during the luteal phase of the menstrual cycle and women should be off oral contraceptives for at least one month prior. If DHEAS is elevated, the adrenal gland is the source of the excess androgens. DHEAS levels greater than 8000 ng/dL are indicative of a possible adrenal tumor. DHEAS levels between 4000 and 8000 ng/dL may indicate the presence of congenital adrenal hyperplasia. If testosterone levels are elevated, while DHEAS levels remain normal, the ovaries are the source of excess androgens. If the total testosterone is greater than 150 to 200 ng/dL an ovarian tumor may be the source. Mild elevations in total testosterone may be indicative of polycystic ovarian syndrome. An increased ratio of LH to FSH is also indicative of this. Patients identified with abnormalities should be appropriately referred to specialists.

Another question that practitioners often ask when starting oral contraceptives is when to initiate Papanicolaou smear screening for cervical cancer prevention, especially in adolescents. The current recommendation of the American College of Obstetricians and Gynecologists written in 2003 is as follows: cervical cancer screening should begin within 3 years after first vaginal intercourse or by age 21, whichever comes first. Guidelines for subsequent screening vary based on age, type of screening test, and prior test results. Physicians prescribing oral contraceptives should routinely ask their

| Table 2 Starting oral contraceptives |
|-----------------------------------|
| **First day start** | **Sunday start** | **Quick start** |
| When to take 1st pill | Started on first day of menses | Started on the first Sunday after the onset of menses | Started anytime during the menstrual cycle after a negative urine pregnancy test |
| Back-up contraception | Back-up contraception not needed but advocated by some for the first week | If Sunday falls on days 1–5 of menses: back-up contraception advocated for the first week | Back-up contraception needed for the first month |
| Advantages | Less chance of pregnancy occurring during first month | Easier pill administration—most packets of pills labeled with day of the week | Better patient compliance |
| Disadvantages | Poorer patient compliance | Poorer patient compliance | Possibility of pregnancy occurring during first month, despite negative initial testing |
patients about their sexual activity and refer their patients to a gynecologist or primary care provider when appropriate.

**Practical management tips**

**How to start oral contraceptives**

cOCPs may be started in three different ways (Table 2). They may be started on the first day of the patient’s menstrual period, within 24 hours of the period commencing. This is known as “First Day Start” method. The theoretical advantage to this method is that there is no need for backup contraception. Despite this, many practitioners still instruct their patients to use backup contraception for the first week.

In the “Sunday Start” method, the first pill is taken on the Sunday following the first day of the last menstrual period. Backup contraception should be used for the first week if it is started between days 1 and 5 of menses. If Sunday falls beyond day 5, backup contraception should be used for the entire first month.

In the “Quick Start” method, cOCPs may be started at any time during the menstrual cycle. This has been shown to increase compliance. In this method, a urine pregnancy test is drawn in the office and, if negative, the patient may begin taking the cOCPs immediately. Some practitioners have their patients take their first pill in the office to increase compliance. Patients should use a backup form of contraception for the first month when using the “Quick Start” method. Fear of undiagnosed pregnancy is a barrier to physician prescription of cOCPs. Physicians may delay pill initiation until the patient’s next period if they have engaged in unprotected intercourse, in fear of teratogenicity. Although cOCPs carry a pregnancy category rating X, according to current literature, exposure to oral contraceptives during early pregnancy is not teratogenic or dangerous to pregnancy. Patients may delay pill initiation until the patient’s next period if they have engaged in unprotected intercourse, in fear of teratogenicity. Although cOCPs carry a pregnancy category rating X, according to current literature, exposure to oral contraceptives during early pregnancy is not teratogenic or dangerous to pregnancy. There is no association between genital and nongenital malformations and the use of low dose oral contraceptives during early pregnancy is not teratogenic or dangerous to pregnancy.

The use of cOCPS in pregnancy for the treatment of acne is obviously contraindicated.

**Spotting/breakthrough bleeding and how to manage**

Spotting and breakthrough bleeding may be a problem for women started on oral contraceptives. Spotting is defined as bleeding not requiring sanitary protection while breakthrough bleeding requires the use of a tampon or menstrual pad. Up to 20% of women stop using oral contraceptives secondary to this side effect. Spotting and breakthrough bleeding are common in the first 3 to 4 months after starting oral contraceptives and patients should be counseled regarding this side effect. After this period, it tends to cease. Both the amount of estrogen and progestin and the type of progestin can contribute to breakthrough bleeding. Estrogen causes uterine lining proliferation and progesterone stabilizes the uterine lining. Too little estrogen or too little progesterone can lead to spotting and breakthrough bleeding. Early cycle bleeding is thought to be secondary to low estrogen and late cycle bleeding to low progesterone. cOCPs with the same amount of estrogen, but different types of progestins, also have significant differences in spotting and breakthrough bleeding. The choice of progestin is thus important. The estrogen to progestrone ratio is also important. In studies where the ratio of estrogen to progesterone was maintained but the concentrations varied, preservation of the ratio was associated with acceptable levels of breakthrough bleeding.

cOCPs are available as monophasic, biphasic, triphasic, extended cycle, and continuous use preparations. Extended cycle and continuous use preparations, which allow for less withdrawal bleeds, have the highest incidence of breakthrough bleeding. Biphasic and triphasic cOCPs were designed to lower the amount of hormones in cOCPs without increasing the incidence of breakthrough bleeding, and possibly decrease this incidence, though evidence has been insufficient to support this.

Other factors that may contribute to breakthrough bleeding include: lack of adherence, smoking, and medication interactions. For example, skipping a pill or failing to take a pill at the same time each day can lead to spotting. In patients who smoke, the habit decreases the estrogenic effectiveness of the pill. This is felt to be secondary to the induction of hepatic estrogen and also progesterone metabolism by cigarette smoking. Smokers have higher rates of menstrual irregularities and more breakthrough bleeding. Also, certain prescription and OTC medications, particularly those that induce the cytochrome P450 system, can cause breakthrough bleeding and can cause contraceptive failure. Examples of common P450 inducers include: rifampin, isoniazid, dexamethasone, griseofulvin, anticonvulsants and alcohol, though the list is more extensive. Pathologic causes of intermenstrual bleeding may mimic breakthrough bleeding and spotting and should be ruled out. For example, uterine or
cervical malignancy and cervicitis from sexually transmitted diseases may cause bleeding between menstrual periods. If bleeding extends beyond 4 months, or begins after a patient has been on a COCP for several months without bleeding, an investigation is warranted.

Strategies for managing breakthrough bleeding are as follows and summarized in Table 3. First, rule out lack of adherence, smoking, medication effect, and pathologic bleeding. Strategies for managing breakthrough bleeding are as follows and summarized in Table 3. First, rule out lack of adherence, smoking, medication effect, and pathologic bleeding. Whether adherence is a factor can be assessed in a number of ways, including history taking, pill counts, and pill counts. Whether adherence is a factor can be assessed in a number of ways, including history taking, pill counts, and pill counts. Whether adherence is a factor can be assessed in a number of ways, including history taking, pill counts, and pill counts. Whether adherence is a factor can be assessed in a number of ways, including history taking, pill counts, and pill counts. Whether adherence is a factor can be assessed in a number of ways, including history taking, pill counts, and pill counts.

Table 3 Strategies for managing breakthrough bleeding*

| Early breakthrough bleeding or spotting | Late breakthrough bleeding or spotting |
|----------------------------------------|---------------------------------------|
| Secondary to low estrogen              | Secondary to low progesterone          |
| Treat with supplemental estrogen:      | Change to a COCP with a more          |
| Estrogen 1.25 mg/day or estradiol      | androgenic progester or higher         |
| 2 mg/day × 7 days                      | amount of progesterin or              |
|                                        | Switch from a multiphasic to a        |
|                                        | monophasic COCP                       |

*First, rule out lack of adherence, smoking, medication effect, and pathologic bleeding.

Disclosures

The authors declare no conflicts of interest.

References

1. Burton J, Cunliffe W, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85(2):119–126.
2. Mallon E, Newton J, Klassen A, et al. Quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672–676.
3. Cunliffe W. Acne and unemployment. Br J Dermatol. 1986;115:386.
4. Kim J, Ochoa M, Krutzik S, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002;169(3):1535–1541.
5. Liu P, Krutzik S, Kim J, et al. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174(5):2467–2470.
6. Cunliffe W, Forster R. Androgen control of the pilosebaceous duct? Br J Dermatol. 1987;116:449.
7. Lookingbill D, Abrams B, Ellis C, et al. Inocoterone and acne. Arch Dermatol. 1992;128:1197–1200.
8. Thiboutot D, Knaggs H, Gilliland K, et al. Activity of type 1 5α-reductase in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol. 1997;136:166–171.
9. Pochi P, Strauss J. Sebaceous gland response in man to the administration of testosterone, D4-androstenedione, and dehydroisoandrostenedione. J Invest Dermatol. 1969;52:32–36.
10. Rony H, Zakon S. Effect of androgen on the sebaceous glands of human skin. Arch Dermatol Syph. 1943;48:601–604.
11. Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol. 1993;139(5):1041–1045.
12. Imperato-McGinley J, Gauthier T, Cai L, et al. The androgen control of sebum production: Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 1996;76:524–528.
13. Chatoud R, Hodgens M, Van der Kwast T, et al. Localization of human androgen receptors in human skin by immunohistochemistry: Implications for the hormonal regulation of hair growth, sebaceous glands, and sweat glands. J Endocrinol. 1991;133:467–475.
14. Liang T, Hoyer S, Yu R. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 1993;100:663–666.
15. Thiboutot D, WenChieh C. Update and future of hormonal therapy in acne. Dermatology. 2003;206;57–67.
16. Thiboutot D. Acne and rosacea: new and emerging therapies. Dermatol Clin. 2000;18:63–71.
17. Pasquale S. Rationale for a triphasic oral contraceptive. J Reprod Med. 1984;29:560–567.
18. Arowojolu A, Gallo M, Lopez L, et al. Combined oral contraceptives for the treatment of acne. Cochrane Database Syst Rev. 2009;(3):CD004425.

19. World Health Organization Collaborative Study of Cardiovascular Diseases and Steroid Hormone Contraception. Venous thromboembolic disease and combine oral contraceptives: Results of international multicenter case-control study. Lancet. 1995;346:1575–1582.

20. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva: WHO; 2004.

21. Bloemenkamp K, Rosendaal F, Helmerhost F, et al. Enhancement by factor V Leiden mutation of risk of deep venous thrombosis associated with oral contraceptives containing the third-generation progestagen. Lancet. 1995;346:1593–1596.

22. Jick H, Kaye I, Vasilakis-Scaramoza C, et al. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives before and after 1995: cohort and case-control analysis. BMJ. 2000;321:1190–1195.

23. Suissa A, Blais L, Spitzer W, et al. First time users of newer oral contraceptives and the risk of venous thromboembolism. Contraception. 1997;56:141–146.

24. Nightingale A, Lawson R, Simpson E, et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care. 2000;5:265–274.

25. Martinez F, Aveccilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007;12(2):97–106.

26. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five year national, case-control study. Contraception. 2002;65:187–196.

27. Pearce H, Layton D, Wilton LV, et al. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol. 2005;60:98–102.

28. Wooltorton E. Diane-35 (cyproterone acetate): safety concerns. Br J Clin Pharmacol. 2005;60:98–102.

29. Seaman H, Vries C, Farmer R. The risk of venous thromboembolism in users of combined oral contraceptives. Contraception. 1995;56:141–149.

30. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism given during the first trimester of pregnancy. Obstet Gynecol. 1995;85:141–149.

31. Dinger J, Heineman L, Kuhl-Habich D. The safety of a drosperinone-ethinyl estradiol oral contraceptive containing 20 microg ethinylestradiol/norethisterone. Contraception. 2006;3:CD003283.

32. Archer J, Archer D. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;6:917–923.

33. Weaver K, Glasier A. Interaction between broad spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception. 1999;59:71–78.

34. Helms S, Bredle D, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36:705–710.

35. London B, Lookingbill D. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives [letter]. Arch Dermatol. 1994;130:392–393.

36. Helms S, Bredle D, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36:705–710.

37. Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start. Obstet Gynecol. 2007;109:1270–1276.

38. Bracken M. Oral contraception and congenital malformation in offspring: a review and meta-analysis of the prospective studies. Obstet Gynecol. 1990;76:522–527.

39. Katz Z, Lancet M, Skorinik J, et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985;65:755–780.

40. Lammer E, Cordero J. Exogenous sex hormone exposure and risk for major malformations. J Am Acad Dermatol. 1986;25:3128–3132.

41. Martinet-Frias M, Rodrigue-Pinilla E, Bermejo E, et al. Prenatal exposure to sex hormones: a case control study. Teratology. 1998;57:4–12.

42. Raman-Wilms L, Tseng A, Wighardt S, et al. Fetal genital effects of first trimester sex hormone exposure: a meta-analysis. Obstet Gynecol. 1994;85:26–149.

43. Lara-Torre E. “Quick Start,” as innovative approach to the combination oral contraceptive pill in adolescents. Is it time to make the switch? J Pediatr Adolesc Gynecol. 2004;17:65–67.

44. Lesniewski R, Prine L. Initiating hormonal contraception. Am Fam Physician. 2006;74(1):105–112.

45. Pratt W, Bachrach C. What do women use when they stop using the pill? Fam Plan Perspect. 1987;19:257–266.

46. Endrikat J, Kronin M, Gerlinger C, et al. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. Contraception. 2001;64:3–10.

47. Lawson JS. Optimum dosing of an oral contraceptive. A report from the study of seven combinations of norgestimate and ethinyl estradiol. Am J Obstet Gyn. 1979;134:315–320.

48. Vee Vlert S, Grimes D, Helmerhorst F, et al. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2006;3:CD003283.

49. Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Met Rev. 1979;9:221–236.

50. Basu J, Mikhail M, Pan J, et al. Endogenous estradiol and progesterone concentrations in smokers on oral contraceptives. Gynecol Obstet Invest. 1992;33:224–227.

51. Rosenberg M, Waugh M, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol. 1996;174:628–632.

52. Lohr P, Creinin M. Oral contraceptives and breakthrough bleeding. What patients need to know. J Fam Pract. 2006;55(10):872–880.